London-based Swiss Life Sciences Group has annnounced its latest move as it looks to benefit from Switzerland’s progressive approach to medical cannabis.
The European state has moved faster than its EU neighbours to provide clear and liberal legal frameworks for the blooming industry.
Swiss Life Sciences, a private equity company, is looking to cash in by ‘identifying strategic investments’ operating within one of the continent’s most progressive environments.
This week, the company has announced the acquisition of Savim SA, an indoor growing facility established in 2016 in Lugano.
According to a statement from the company, the growing cycle at the site is ‘managed by a proprietary blockchain technology’ and ‘each stage of the plant’s life cycle is recorded and managed with no human intervention, other than the artisan expertise of our grower technicians’.
Kevin Du Plessis, CEO of Swiss Life Sciences Group, said: “Our biggest and most important investment to date has been in time – time to research and identify the optimum sweet spots and opportunities in the fast-evolving phytocannabinoid industry.
“That time has been well spent, and working with our team of professional consultants and advisors has allowed us to establish a real Tesla-style approach to our thinking.
“Starting with a future-proof cannabis facility in Switzerland, this will feed into state-of-the-art extraction and end-products production across the whole spectrum of the industry, from wellness and cosmetics to medical healthcare and even pet care.
“It is truly amazing, the different product ranges to which we can apply our raw materials and extracts.
“Our cultivation system has already shown average yield increases of 15% over normal indoor growing facilities, and the consistency of the end cannabis flowers is simply perfection.
“Nature is a wondrous thing, but when you add passion to science, you can create products that really raise the bar and set the standard.”
Swiss Life Sciences has not disclosed the cost of the deal for the 17,000m2 site.
Jean-Pierre Engele, COO of Savim SA, said: “Having SLSG as overseer and a ‘guiding light’ will allow us to design and establish what we believe will become a flagship facility for the future of the CBD and cannabinoids industry.
“We firmly believe that with our strong trusted partnerships and our ability to control – and demonstrate with full transparency – our husbandry, from plant genetics to end products, with strong ethical and compliance-led drivers, is key to developing a future-proof, fully controlled and regulated industry, with the benefits to end consumers in mind.”